Viridian Therapeutics, Inc.

NasdaqCM VRDN

Viridian Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -4.31

Viridian Therapeutics, Inc. EPS (Diluted) is USD -4.31 for the Trailing 12 Months (TTM) ending September 30, 2024, a 14.14% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Viridian Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -5.02, a 8.06% change year over year.
Viridian Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -5.46, a 81.47% change year over year.
Viridian Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -29.46, a -176.88% change year over year.
Viridian Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -10.64, a 47.84% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: VRDN

Viridian Therapeutics, Inc.

CEO	Mr. Stephen F. Mahoney J.D., MBA
IPO Date	June 18, 2014
Location	United States
Headquarters	221 Crescent Street
Employees	94
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years